The Claim

Tirzepatide reduces serum uric acid levels in individuals with obesity or overweight, with no significant difference in the magnitude of reduction between men and women.

Source: Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
72score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

Tirzepatide lowers serum uric acid levels in people with obesity or overweight, and the amount of reduction is similar in men and women.

See the scientific wording

Tirzepatide reduces serum uric acid levels in both men and women with obesity or overweight, with no significant difference in effect size between sexes, despite gout being more common in men.

Why this might work

Losing weight reduces fat tissue, which lowers the body's production of uric acid and helps the kidneys remove more of it from the blood.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial.

    Tirzepatide lowered uric acid in people with obesity, and while the study didn’t break down results by sex, it showed the effect was consistent across different groups — so it doesn’t contradict the idea that it works equally well in men and women.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.